Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Tilray Inc    TLRY

TILRAY INC

(TLRY)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
44.18(c) 44.58(c) 46.24(c) 44.79(c) 43.88(c) Last
1 187 646 898 730 1 492 717 881 422 731 362 Volume
-3.24% +0.91% +3.72% -3.14% -2.03% Change
More quotes
Financials (USD)
Sales 2019 178 M
EBIT 2019 -56,6 M
Net income 2019 -47,8 M
Debt 2019 -
Yield 2019 -
Sales 2020 357 M
EBIT 2020 9,24 M
Net income 2020 -2,86 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 24,4x
Capi. / Sales2020 12,2x
Capitalization 4 355 M
More Financials
Company
Tilray Inc is engaged in pharmaceutical sector. The Company is a supplier of cannabis products to pharmaceutical distributors. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Through its subsidiary, FHF Holdings Ltd... 
Sector
Pharmaceuticals
Calendar
05/30 | 01:00pmShareholder meeting
More about the company
Surperformance© ratings of Tilray Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on TILRAY INC
06:42aTILRAY : Boosts Export Capability With EU Manufacturing License, GMP Certificati..
AQ
05/24TILRAY : Boosts International Export Capacity with Manufacturing License and GMP..
AQ
05/23TILRAY : reg; Boosts International Export Capacity with Manufacturing License an..
BU
05/15TILRAY : Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/14AURORA CANNABIS : Tilray, Aurora Cannabis sales jump after Canada legalizes recr..
RE
05/14TILRAY : revenue soars nearly 200%, net loss grows in first quarter
AQ
05/14TILRAY, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
05/14TILRAY : Inc. Reports First Quarter 2019 Financial Results
BU
05/13TILRAY : Financial Statements and Exhibits (form 8-K/A)
AQ
05/12TILRAY : Five things to watch for in the Canadian business world in the coming w..
AQ
More news
Analyst Recommendations on TILRAY INC
More recommendations
Sector news : Pharmaceuticals - NEC
05/24NOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
05/24NOVARTIS : Correction to Novartis Article
DJ
05/24NOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
05/24NOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $2.12..
DJ
05/24SAMSUNG ELECTRONICS : South Korea orders further arrests at Samsung Electronics ..
RE
More sector news : Pharmaceuticals - NEC
Chart TILRAY INC
Duration : Period :
Tilray Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TILRAY INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 94,9 $
Spread / Average Target 112%
EPS Revisions
Managers
NameTitle
Brendan Kennedy President, Chief Executive Officer & Director
Greg Christopher Executive Vice President-Operations
Mark Castaneda Chief Financial Officer, Secretary & Treasurer
Joshua Eades Chief Science Officer & Vice President
Christine Thompson St. Clare Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TILRAY INC-37.79%4 355
JOHNSON & JOHNSON8.32%368 655
PFIZER-3.96%233 239
ROCHE HOLDING LTD.11.42%233 096
NOVARTIS17.44%219 832
MERCK AND COMPANY6.23%208 984